COVID-19: Updated Data and its Relation to the Cardiovascular System
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Tipo de documento: | preprint |
Idioma: | eng |
Título da fonte: | SciELO Preprints |
Texto Completo: | https://preprints.scielo.org/index.php/scielo/preprint/view/426 |
Resumo: | In December 2019, a new human coronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) or coronavirus disease 2019 (COVID‑19) by the World Health Organization, emerged in the city of Wuhan, China. Spreading globally, it is now considered pandemic, with approximately 3 million cases worldwide at the end of April. Its symptoms include fever, cough, and headache, but the main one is shortness of breath. In turn, it is believed that there is a relationship between COVID‑19 and damage to the heart muscle, and hypertensive and diabetic patients, for example, seem to have worse prognosis. Therefore, COVID‑19 may worsen in individuals with underlying adverse conditions, and a not negligible number of patients hospitalized with this virus had cardiovascular or cerebrovascular diseases. Systemic inflammatory response and immune system disorders during disease progression may be behind this association. In addition, the virus uses angiotensin‑converting enzyme (ACE) receptors, more precisely ACE2, to penetrate the cell; therefore, the use of ACE inhibitor drugs and angiotensin receptor blockers could cause an increase in these receptors, thus facilitating the entry of the virus into the cell. There is, however, no scientific evidence to support the interruption of these drugs. Since they are fundamental for certain chronic diseases, the risk and benefit of their withdrawal in this scenario should be carefully weighed. Finally, cardiologists and health professionals should be aware of the risks of infection and protect themselves as much as possible, sleeping properly and avoiding long working hours. |
id |
SCI-1_a8682893fffe87e996a5c2953f96dd61 |
---|---|
oai_identifier_str |
oai:ops.preprints.scielo.org:preprint/426 |
network_acronym_str |
SCI-1 |
network_name_str |
SciELO Preprints |
repository_id_str |
|
spelling |
COVID-19: Updated Data and its Relation to the Cardiovascular SystemCOVID-19: Updated Data and its Relation to the Cardiovascular SystemCOVID-19: Updated Data and its Relation to the Cardiovascular SystemCoronavirusCOVID 19Acute Respiratory Syndromecardiovascular Diseases/complicationsMyocarditisInfectious DiseasesRisk Factors/prevention and controlIn December 2019, a new human coronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) or coronavirus disease 2019 (COVID‑19) by the World Health Organization, emerged in the city of Wuhan, China. Spreading globally, it is now considered pandemic, with approximately 3 million cases worldwide at the end of April. Its symptoms include fever, cough, and headache, but the main one is shortness of breath. In turn, it is believed that there is a relationship between COVID‑19 and damage to the heart muscle, and hypertensive and diabetic patients, for example, seem to have worse prognosis. Therefore, COVID‑19 may worsen in individuals with underlying adverse conditions, and a not negligible number of patients hospitalized with this virus had cardiovascular or cerebrovascular diseases. Systemic inflammatory response and immune system disorders during disease progression may be behind this association. In addition, the virus uses angiotensin‑converting enzyme (ACE) receptors, more precisely ACE2, to penetrate the cell; therefore, the use of ACE inhibitor drugs and angiotensin receptor blockers could cause an increase in these receptors, thus facilitating the entry of the virus into the cell. There is, however, no scientific evidence to support the interruption of these drugs. Since they are fundamental for certain chronic diseases, the risk and benefit of their withdrawal in this scenario should be carefully weighed. Finally, cardiologists and health professionals should be aware of the risks of infection and protect themselves as much as possible, sleeping properly and avoiding long working hours.SciELO PreprintsSciELO PreprintsSciELO Preprints2020-05-11info:eu-repo/semantics/preprintinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://preprints.scielo.org/index.php/scielo/preprint/view/426enghttps://preprints.scielo.org/index.php/scielo/article/view/426/533Copyright (c) 2020 Filipe Ferrarihttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessFerrari, Filipereponame:SciELO Preprintsinstname:SciELOinstacron:SCI2020-05-11T16:40:55Zoai:ops.preprints.scielo.org:preprint/426Servidor de preprintshttps://preprints.scielo.org/index.php/scieloONGhttps://preprints.scielo.org/index.php/scielo/oaiscielo.submission@scielo.orgopendoar:2020-05-11T16:40:55SciELO Preprints - SciELOfalse |
dc.title.none.fl_str_mv |
COVID-19: Updated Data and its Relation to the Cardiovascular System COVID-19: Updated Data and its Relation to the Cardiovascular System COVID-19: Updated Data and its Relation to the Cardiovascular System |
title |
COVID-19: Updated Data and its Relation to the Cardiovascular System |
spellingShingle |
COVID-19: Updated Data and its Relation to the Cardiovascular System Ferrari, Filipe Coronavirus COVID 19 Acute Respiratory Syndrome cardiovascular Diseases/complications Myocarditis Infectious Diseases Risk Factors/prevention and control |
title_short |
COVID-19: Updated Data and its Relation to the Cardiovascular System |
title_full |
COVID-19: Updated Data and its Relation to the Cardiovascular System |
title_fullStr |
COVID-19: Updated Data and its Relation to the Cardiovascular System |
title_full_unstemmed |
COVID-19: Updated Data and its Relation to the Cardiovascular System |
title_sort |
COVID-19: Updated Data and its Relation to the Cardiovascular System |
author |
Ferrari, Filipe |
author_facet |
Ferrari, Filipe |
author_role |
author |
dc.contributor.author.fl_str_mv |
Ferrari, Filipe |
dc.subject.por.fl_str_mv |
Coronavirus COVID 19 Acute Respiratory Syndrome cardiovascular Diseases/complications Myocarditis Infectious Diseases Risk Factors/prevention and control |
topic |
Coronavirus COVID 19 Acute Respiratory Syndrome cardiovascular Diseases/complications Myocarditis Infectious Diseases Risk Factors/prevention and control |
description |
In December 2019, a new human coronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) or coronavirus disease 2019 (COVID‑19) by the World Health Organization, emerged in the city of Wuhan, China. Spreading globally, it is now considered pandemic, with approximately 3 million cases worldwide at the end of April. Its symptoms include fever, cough, and headache, but the main one is shortness of breath. In turn, it is believed that there is a relationship between COVID‑19 and damage to the heart muscle, and hypertensive and diabetic patients, for example, seem to have worse prognosis. Therefore, COVID‑19 may worsen in individuals with underlying adverse conditions, and a not negligible number of patients hospitalized with this virus had cardiovascular or cerebrovascular diseases. Systemic inflammatory response and immune system disorders during disease progression may be behind this association. In addition, the virus uses angiotensin‑converting enzyme (ACE) receptors, more precisely ACE2, to penetrate the cell; therefore, the use of ACE inhibitor drugs and angiotensin receptor blockers could cause an increase in these receptors, thus facilitating the entry of the virus into the cell. There is, however, no scientific evidence to support the interruption of these drugs. Since they are fundamental for certain chronic diseases, the risk and benefit of their withdrawal in this scenario should be carefully weighed. Finally, cardiologists and health professionals should be aware of the risks of infection and protect themselves as much as possible, sleeping properly and avoiding long working hours. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-05-11 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/preprint info:eu-repo/semantics/publishedVersion |
format |
preprint |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://preprints.scielo.org/index.php/scielo/preprint/view/426 |
url |
https://preprints.scielo.org/index.php/scielo/preprint/view/426 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://preprints.scielo.org/index.php/scielo/article/view/426/533 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2020 Filipe Ferrari https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2020 Filipe Ferrari https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
SciELO Preprints SciELO Preprints SciELO Preprints |
publisher.none.fl_str_mv |
SciELO Preprints SciELO Preprints SciELO Preprints |
dc.source.none.fl_str_mv |
reponame:SciELO Preprints instname:SciELO instacron:SCI |
instname_str |
SciELO |
instacron_str |
SCI |
institution |
SCI |
reponame_str |
SciELO Preprints |
collection |
SciELO Preprints |
repository.name.fl_str_mv |
SciELO Preprints - SciELO |
repository.mail.fl_str_mv |
scielo.submission@scielo.org |
_version_ |
1797047817342025728 |